StockData

Syndax Pharmaceuticals vs Zai Lab

SNDX and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SNDX and ZLAB compare

Zai Lab is the larger company, worth 44 times as much as Syndax Pharmaceuticals ($36.5B against $822M).

Syndax Pharmaceuticals grew revenue faster over the last twelve months (160% versus 5.1% for Zai Lab).

Zai Lab keeps more of each dollar of sales as profit, with a net margin of −41.9% compared with −72.3% at Syndax Pharmaceuticals.

Zai Lab scores higher on the StockData Score (7 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSNDXZLAB
Size and price
Market cap$822M$36.5B
Share price$9.20$23.53
Change, 1 year−44.6%8.2%
Change, 5 years−44.2%−69.4%
Beta (5Y)1.721.45
Employees2981,784
StockData Score
Total score37 (better)
Valuation score1 (better)0
Growth score11
Performance score03 (better)
Health score13 (better)
Dividend score00
Valuation
P/S2.8× (better)81.3×
P/B–60.2×
FCF yield–−0.38%
Fair value–$4.52
Margin of safety–−421%
Growth
Revenue growth (TTM)160% (better)5.1%
Revenue growth, 5Y average158% (better)56.5%
Profitability
Gross margin–56.5%
Operating margin−61.7%−58.7% (better)
Net margin−72.3%−41.9% (better)
FCF margin–−31.0%
Return on equity−426%−26.9% (better)
Return on invested capital–−90.4%
Financial health
Debt / equity–0.39
Interest coverage−44660.0×−44.1× (better)
Current ratio4.69 (better)2.13
Altman Z-score−2.3043.47 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions121%2.8%
Held by insiders1.8%0.67%
Insider net buying, 12 months−$2.9M (better)−$10.7M
Short interest, % of float21.6%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.